Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic therapy.

A C Wolff1

  • 1The Johns Hopkins Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231-1000, USA. awolff@jhmi.edu

Current Opinion in Oncology
|October 24, 2001
PubMed
Summary
This summary is machine-generated.

Recent advancements in systemic therapy for breast cancer include new findings on risk reduction, patient selection, and novel agents like trastuzumab. This review covers key developments and long-term effects of adjuvant therapy since 2000.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer.

ESMO open·2026
Same author

Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

HER2DX genomic test in early-stage HER2-positive breast cancer.

ESMO open·2024
Same author

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].

ESMO open·2024
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Area of Science:

  • Oncology
  • Breast Cancer Research

Background:

  • Significant new data on systemic therapy for breast cancer has emerged, focusing on primary risk reduction and patient selection for adjuvant treatments.
  • Key developments include insights into anthracycline analogs, ongoing adjuvant trials (e.g., taxane studies), and ovarian ablation data presented at the 2000 National Institutes of Health Consensus Development Conference.

Purpose of the Study:

  • To review and examine important ongoing developments in adjuvant and systemic therapy for breast cancer since 2000.
  • To highlight new data on anti-estrogen therapies, novel compounds, and the long-term effects of treatment.

Main Methods:

  • Review of recently published data on systemic breast cancer therapy.
  • Analysis of information presented at the November 2000 National Institutes of Health Consensus Development Conference.

Related Experiment Videos

  • Inclusion of unpublished updates from the fourth Oxford Overview (September 2000).

    • Main Results:

    • New data expands the role of anti-estrogen therapy, including aromatase inhibitors and pure antiestrogens.
    • Trastuzumab and other novel compounds are under investigation as single agents and in combination therapies.
    • Discussions on the long-term effects of adjuvant therapy are increasingly prominent.

    Conclusions:

    • The landscape of systemic breast cancer therapy has evolved significantly with new data on risk reduction, targeted agents, and treatment sequencing.
    • Continued research into novel compounds and understanding long-term effects are crucial for optimizing breast cancer management.